By Fineline Cube 
US giant Pfizer Inc. (NYSE: PFE) announced that its Emblaveo (aztreonam and avibactam) has been prescribed for the first time nationwide in several hospitals in Shanghai. The drug received approval from China’s National Medical Products Administration (NMPA) in June 2025 for treating adult patients with complex intra-abdominal infections (cIAI) and hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), caused by Gram-negative bacteria with limited or no alternative treatment options.
Drug Mechanism
Emblaveo is the first β-lactam/β-lactamase inhibitor combination targeting bacteria producing metallo-β-lactamases (MBLs) and covering all enzyme types of carbapenem-resistant Enterobacterales (CRE). This combination provides a new treatment option for infections caused by multidrug-resistant Gram-negative bacteria.
Clinical Significance
The launch of Emblaveo marks a significant breakthrough in China’s efforts to combat infections caused by multidrug-resistant Gram-negative bacteria. It ushers in a new era of precision medicine in anti-infective therapy, offering hope for patients with limited treatment options.-Fineline Info & Tech